78 Patients Take Part in Five-Year, Retrospective University of Wisconsin
Study
IRVINE, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies used by urologists and interventional radiologists for tissue and tumor ablation, announced today that a new five-year retrospective study published in the October issue of the British Journal of Urology demonstrates that cryoablation is an effective treatment for patients with small kidney tumors.
A total of 78 patients who had 88 small tumors (mean tumor size was 2.6 cm in diameter) took part in the study led by Stephen Y. Nakada, M.D., of the Division of Urology at the University of Wisconsin, Madison. The cancerous lesions were ablated through either laparoscopic or percutaneous cryoablation in one operative procedure in 95 percent of the cases and, after a mean follow-up of 19 months, the cancer-specific survival rate was 100 percent and recurrence-free survival rate was 98.7 percent.
Dr. Nakada and the researchers noted that the collaboration between urologists and radiologists is optimal for these patients to best target and guide the ablations. He added that cryoablation was most appropriate for kidney tumors 4 cm or less in diameter.
Craig T. Davenport, President, CEO and Chairman of Endocare, said that
"Dr. Nakada's five-year experience is providing additional confirmation and
results that support the growing body of academic research that
cryoablation treatment for kidney tumors is effective. The results from Dr.
Nakada and his colleagues at the University of Wisconsin are quite
impressive and
'/>"/>
| SOURCE Endocare, Inc. Copyright©2007 PR Newswire. All rights reserved |